glp·helper
glphelper.com/zepbound/virginia/virginia-beach
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in Virginia Beach, VA

Verified Zepbound providers in Virginia Beach, VA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Zepbound weight loss →trial-anchored estimate
city providers
35
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Virginia
35 of 35 shown

Find a Zepbound provider in Virginia.

Every entry is checked against the NPI registry and the Virginia medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Virginia city · /zepbound/virginia/{city}
§ 03Getting Zepbound in Virginia Beach
35 providers · Virginia Beach, VA

How to get Zepbound in Virginia Beach.

35 GLP-1 prescribers and 7 local resource types are on record for Virginia Beach, plus 3 nearby towns in the directory.

Prescribers in Virginia Beach
35 prescribers
35 GLP-1 prescribers in Virginia Beach, most listed as Family Medicine (12), Internal Medicine, Endocrinology, Diabetes & Metabolism (11) and Internal Medicine (11). Any Virginia-licensed physician, nurse practitioner, or PA can prescribe Zepbound, over video or in person. The nearest towns on record are Norfolk (37 providers), Richmond (41 providers) and Arlington (36 providers).
Around the prescription in Virginia Beach
7 listed nearby
6 dietitians, 5 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Virginia Beach.
Medicaid (weight loss)
Covered
As of April 2026, Virginia Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Virginia’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition)
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Virginia

Diagnosed diabetes reaches 10.4% of adults in Virginia.

of Virginia adults have obesity
32.3%
diagnosed diabetes
10.4%

Age-adjusted estimates for Virginia, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossthe tirzepatide dosing schedule
§ 05Support around Zepbound in Virginia Beach
6 gyms

The prescription is one part. Here is the rest, in Virginia Beach.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Virginia Beach, VA, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Crunch Fitness - Chimney Hill
GYM
4.4 on Google · 1031 reviews
799 Chimney Hill Pkwy
Website
Planet Fitness
GYM
4.3 on Google · 760 reviews
3877 Holland Rd Ste 426
Website
Onelife Fitness - Red Mill
GYM
4.6 on Google · 748 reviews
1650 General Booth Blvd
Website
StretchLab
FITNESS
5.0 on Google · 607 reviews
2208 General Booth Blvd Ste 310
Website
Onelife Fitness - Princess Anne Gym
GYM
4.6 on Google · 567 reviews
3809 Princess Anne Rd
Website
CYCLEBAR
FITNESS
5.0 on Google · 526 reviews
1624 Laskin Rd #752
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Jenna Albert, RDN
RD
Registered dietitian
4401 Fairfax Dr Ste 205
Call 571-328-7408NPI 1194350124
Shaye Arluk, MS, RDN
RD
Registered dietitian
6251 E Virginia Beach Blvd
Call 888-220-2214NPI 1235863671
Jennifer Armstrong, MS, RD
RD
Registered dietitian
1219 Sir George Cir
Call 508-561-9972NPI 1184549578
Brittany Bailey
RD
Registered dietitian
5757 Accomac Sq
Call 931-797-5498NPI 1023635265
Sheila Bailey, R.D.,
RD
Registered dietitian
4752 Hollis Rd
Call 757-466-7420NPI 1518932375
Lauren Barkan, MS, RD
RD
Registered dietitian
1009 Downshire Chase
Call 757-636-6097NPI 1376249623
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Zepbound cash price (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Commercial insurance (weight)
Often denied
On-label for obesity but frequently requires prior authorization
Medicare Part D
Not covered
Weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance with coverage only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Zepbound providers in Virginia

NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Zepbound in other states

Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Zepbound in Virginia

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]